Plasma levels of free vascular endothelial growth factor 165 (VEGF 165 ) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): Results of a prospective cohort study with matched controls

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 96, Issue 2, 2001, Pages 196-201

  Enskog, Anders ^a   Nilsson, Lars ^a   Brännström, Mats ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Follicle; IVF; OHSS; Progesterone; VEGF

Indexed keywords

BUSERELIN; GONADOTROPIN; PROGESTERONE; VASCULOTROPIN;

ADULT; ARTICLE; ASPIRATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EMBRYO TRANSFER; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GONADOTROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; OOCYTE; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY;

EID: 0034982978     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(00)00460-7     Document Type: Article

References (40)

1. Severe ovarian hyperstimulation syndrome: Serum and ascitic fluid concentrations of vascular endothelial growth factor
2. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome
3. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
4. Correlation between the amount of follicle-stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations undergoing in vitro fertilization
5. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program
6. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome
7. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression
8. Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle
9. Interleukin-6 induces the expression of vascular endothelial growth factor
10. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
11. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
12. Editorial, ovarian hyperstimulation syndrome
13. The pathophysiology of ovarian hyperstimulation syndrome - Views and ideas
14. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization
15. Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome
16. Role of vascular endothelial growth factor in the regulation of angiogenesis
17. Peripheral blood T-lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T-cells in angiogenesis
18. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome
19. Intracellular pool of vascular endothelial growth factor in human neutrophils
20. Interleukin-10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis
21. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats
22. Interleukin-6 is a potent thrombopoietic factor in vivo in mice
23. Expression of the fms-like tyrosine kinase-4 gene becomes restricted to lymphatic endothelium during development
24. Expression of interleukin-6 and interleukin-6 receptors in human granulosa lutein cells
25. Vascular permeability factor, an endothelial cell mitogen related to PDGF
26. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: A preliminary report
27. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization
28. HCG does not directly regulate circulating concentrations of vascular endothelial growth factor in IVF and embryo transfer cycles
29. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration
30. Early and late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different risk factors
31. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome
32. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome
33. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
34. The ovarian hyperstimulation syndrome
35. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome
36. Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent
37. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
38. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
39. Platelet: Transporter of vascular endothelial growth factor
40. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro